NCT00856713

Clearance of NRL972 in Patients With Cirrhosis and in Healthy Volunteers

A Study in Healthy Volunteers and Patients With Liver Cirrhosis to Assess the Effects of Age, Gender, and Stable Liver Disease on the Clearance of Cholyl-Lysyl-Fluorescein (NRL972) as an in-Vivo Marker of Liver Function in Man

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 72 (actual)
• Sponsor: Norgine · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

A study in healthy volunteers and patients with liver cirrhosis to assess the effects of age, gender, and stable liver disease on the clearance of cholyl-lysyl-fluorescein (NRL972)

Conditions

• Hepatic Cirrhosis

Interventions

Type	Name	Description
DRUG	NRL972	Single intravenous dose of 2 mg NRL972
DRUG	NRL972	Single intravenous dose of 2 mg NRL972
DRUG	NRL972	Single intravenous dose of 2 mg NRL972
DRUG	NRL972	Single intravenous dose of 2 mg NRL972
DRUG	NRL972	Single intravenous dose of 2 mg NRL972
DRUG	NRL972	Single intravenous dose of 2 mg NRL972

Timeline

• Start date: 2006-03-01
• Primary completion: 2006-08-01
• First posted: 2009-03-06
• Last updated: 2009-03-06

Locations

1 site across 1 country: Bulgaria